Ernexa Therapeutics Inc. Increase (Decrease) in Other Noncurrent Assets
Ernexa Therapeutics Inc. (ERNA) reported Increase (Decrease) in Other Noncurrent Assets of -$85.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentAssets · last filed 2026-08-06
- Ernexa Therapeutics Inc. increase (decrease) in other noncurrent assets for the quarter ending 2025-12-31 was -$6.00K.
- Ernexa Therapeutics Inc. increase (decrease) in other noncurrent assets for the quarter ending 2025-09-30 was -$1.00K.
- Ernexa Therapeutics Inc. increase (decrease) in other noncurrent assets for the quarter ending 2025-06-30 was $0.00.
- Ernexa Therapeutics Inc. increase (decrease) in other noncurrent assets for the quarter ending 2025-03-31 was -$1.00K.
- Ernexa Therapeutics Inc. increase (decrease) in other noncurrent assets for fiscal 2025 was -$8.00K.
- Ernexa Therapeutics Inc. increase (decrease) in other noncurrent assets for fiscal 2024 was -$2.00K.
- Ernexa Therapeutics Inc. increase (decrease) in other noncurrent assets for fiscal 2023 was -$1.01M, a 256.97% decline from fiscal 2022.
- Ernexa Therapeutics Inc. increase (decrease) in other noncurrent assets for fiscal 2022 was $646.00K.
| Period end | Increase (Decrease) in Other Noncurrent Assets 3 month | Increase (Decrease) in Other Noncurrent Assets 6 month | Increase (Decrease) in Other Noncurrent Assets 9 month | Increase (Decrease) in Other Noncurrent Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$85.00K 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | -$6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$7.00K derived: sum of 2 quarters · filed 2026-03-13 | -$7.00K derived: sum of 3 quarters · filed 2026-08-06 | -$8.00K 10-K · filed 2026-03-13 |
| 2025-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$1.00K derived: sum of 2 quarters · filed 2026-08-06 | -$2.00K 10-Q · filed 2025-11-07 | -$3.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.00K 10-Q · filed 2026-08-06 | -$2.00K derived: sum of 3 quarters · filed 2026-08-06 | -$2.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$1.00K 10-Q · filed 2026-05-11 | -$2.00K derived: sum of 2 quarters · filed 2026-05-11 | -$2.00K derived: sum of 3 quarters · filed 2026-05-11 | -$3.00K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$1.00K derived: sum of 2 quarters · filed 2026-03-13 | -$2.00K derived: sum of 3 quarters · filed 2026-03-13 | -$2.00K 10-K · filed 2026-03-13 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$1.00K derived: sum of 2 quarters · filed 2025-11-07 | -$1.00K 10-Q · filed 2025-11-07 | -$3.93M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$1.00K 10-Q · filed 2025-08-13 | -$3.93M derived: sum of 3 quarters · filed 2025-08-13 | -$1.50M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-14 | -$3.92M derived: sum of 2 quarters · filed 2025-03-12 | -$1.50M derived: sum of 3 quarters · filed 2025-03-12 | -$1.12M derived: sum of 4 quarters · filed 2025-03-12 |
| 2023-12-31 | -$3.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | -$1.50M derived: sum of 2 quarters · filed 2025-03-12 | -$1.12M derived: sum of 3 quarters · filed 2025-03-12 | -$1.01M 10-K · filed 2025-03-12 |
| 2023-09-30 | $2.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $2.80M derived: sum of 2 quarters · filed 2024-11-12 | $2.91M 10-Q · filed 2024-11-12 | $3.23M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $373.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $481.00K 10-Q · filed 2024-08-13 | $796.00K derived: sum of 3 quarters · filed 2024-08-13 | $1.14M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $108.00K 10-Q · filed 2024-05-14 | $423.00K derived: sum of 2 quarters · filed 2024-05-14 | $765.00K derived: sum of 3 quarters · filed 2024-05-14 | $820.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $315.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $657.00K derived: sum of 2 quarters · filed 2024-03-14 | $712.00K derived: sum of 3 quarters · filed 2024-03-14 | $646.00K 10-K · filed 2024-03-14 |
| 2022-09-30 | $342.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $397.00K derived: sum of 2 quarters · filed 2023-11-13 | $331.00K 10-Q · filed 2023-11-13 | $300.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $55.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$11.00K 10-Q · filed 2023-08-11 | -$42.00K derived: sum of 3 quarters · filed 2023-08-11 | |
| 2022-03-31 | -$66.00K 10-Q · filed 2023-05-11 | -$97.00K derived: sum of 2 quarters · filed 2023-05-11 | ||
| 2021-12-31 | -$31.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $0.00 10-K · filed 2023-03-20 | ||
| 2021-09-30 | $31.00K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |